Burchell JM - Search Results

1

Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope.

Heukamp LC, van Hall T, Ossendorp F, Burchell JM, Melief CJ, Taylor-Papadimitriou J, Offringa R. Heukamp LC, et al. Among authors: burchell jm. J Immunother. 2002 Jan-Feb;25(1):46-56. doi: 10.1097/00002371-200201000-00005. J Immunother. 2002. PMID: 11926165

2

MUC1 and the immunobiology of cancer.

Taylor-Papadimitriou J, Burchell JM, Plunkett T, Graham R, Correa I, Miles D, Smith M. Taylor-Papadimitriou J, et al. Among authors: burchell jm. J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21. doi: 10.1023/a:1020360121451. J Mammary Gland Biol Neoplasia. 2002. PMID: 12463741 Review.

3

MUC1 immunotherapy.

Beatson RE, Taylor-Papadimitriou J, Burchell JM. Beatson RE, et al. Among authors: burchell jm. Immunotherapy. 2010 May;2(3):305-27. doi: 10.2217/imt.10.17. Immunotherapy. 2010. PMID: 20635898 Review.

4

Sialylated core 1 based O-linked glycans enhance the growth rate of mammary carcinoma cells in MUC1 transgenic mice.

Mungul A, Cooper L, Brockhausen I, Ryder K, Mandel U, Clausen H, Rughetti A, Miles DW, Taylor-Papadimitriou J, Burchell JM. Mungul A, et al. Among authors: burchell jm. Int J Oncol. 2004 Oct;25(4):937-43. Int J Oncol. 2004. PMID: 15375543

5

Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor.

Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, Arif S, Mather SJ, Taylor-Papadimitriou J, Burchell JM, Maher J. Wilkie S, et al. Among authors: burchell jm. J Immunol. 2008 Apr 1;180(7):4901-9. doi: 10.4049/jimmunol.180.7.4901. J Immunol. 2008. PMID: 18354214

6

Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas.

Picco G, Beatson R, Taylor-Papadimitriou J, Burchell JM. Picco G, et al. Among authors: burchell jm. Eur J Immunol. 2014 Jul;44(7):1947-55. doi: 10.1002/eji.201344076. Epub 2014 Apr 17. Eur J Immunol. 2014. PMID: 24648154 Free PMC article.

7

Latest developments in MUC1 immunotherapy.

Taylor-Papadimitriou J, Burchell JM, Graham R, Beatson R. Taylor-Papadimitriou J, et al. Among authors: burchell jm. Biochem Soc Trans. 2018 Jun 19;46(3):659-668. doi: 10.1042/BST20170400. Epub 2018 May 21. Biochem Soc Trans. 2018. PMID: 29784646 Free PMC article. Review.

8

Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells.

Graham RA, Burchell JM, Beverley P, Taylor-Papadimitriou J. Graham RA, et al. Among authors: burchell jm. Int J Cancer. 1996 Mar 1;65(5):664-70. doi: 10.1002/(SICI)1097-0215(19960301)65:5<664::AID-IJC17>3.0.CO;2-7. Int J Cancer. 1996. PMID: 8598319 Free article.

9

The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine.

Graham RA, Burchell JM, Taylor-Papadimitriou J. Graham RA, et al. Among authors: burchell jm. Cancer Immunol Immunother. 1996 Feb;42(2):71-80. doi: 10.1007/s002620050254. Cancer Immunol Immunother. 1996. PMID: 8620523 Free PMC article. Review.

10

Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice.

Smith M, Burchell JM, Graham R, Cohen EP, Taylor-Papadimitriou J. Smith M, et al. Among authors: burchell jm. Immunology. 1999 Aug;97(4):648-55. doi: 10.1046/j.1365-2567.1999.00831.x. Immunology. 1999. PMID: 10457219 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

136 results

Search Page